First human trial for coronavirus vaccine starts in US

James Marshall
March 29, 2020

Two days after the United States began human trials of a potential coronavirus vaccine, China has also given the go-ahead for another drug.

Dozens of research groups around the world are racing to create a vaccine as COVID-19 cases continue to grow.

"There are some work units that made rapid progress in the development (of vaccines) and have submitted applications for clinical trials to the National Medical Products Administration".

China's Academy of Military Medical Sciences and the Hong Kong-based biotech firm CanSino Biologics will jointly conduct the trial.

The database also showed that "Phase 1" will comprise of examining whether the experimental shot is safe or not, by trialing it on 108 healthy volunteers between March 16 and December 31.

Clinical trials of a coronavirus vaccine being developed for the Coronavirus pandemic has started yesterday in the US, and a Microsoft network engineer has been one of the first to receive the experimental product.

Called mRNA-1273, the vaccine was developed by NIAID scientists and their collaborators at the biotechnology company Moderna, Inc. Each participant will receive two shots, 28 days apart.

Three of the study participants spoke to The Associated Press on Monday.

The trial has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle, and is funded by the NIAID, part of the National Institutes of Health (NIH). The participants will be followed up with 12 months after the second vaccination. They will be checked for side effects and have their blood tested to determine whether the vaccine is revving up their immune systems.

Notable other researchers have suggested a vaccine could be available much sooner, with a team from the University of Queensland suggesting they could have a vaccine on the market by the end of the year.

According to Fauci, even if initial safety tests go well, it may take about a year to 18 months before any vaccine could be ready for public use.

The vaccine, mRNA-1273, was not tested in mice before beginning human clinical trials.

However, some experts say it is justified considering the severity and urgent need of the current situation.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER